Anaptys Announces Participation in November Investor Conferences

Phase 2Phase 3Immunotherapy
Anaptys Announces Participation in November Investor Conferences
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences in November:
Investor Conference Details
Guggenheim 5th Annual I&I Conference, New York, NY
Format – Fireside chat and one-on-one investor meetings
Date and Time – Tuesday, Nov. 7, 2023 at 9:50am ET / 6:50am PT
UBS Biopharma Conference 2023, Miami, FL
Format – One-on-one investor meetings
Date – Wednesday, Nov. 8, 2023
Stifel 2023 Healthcare Conference, New York, NY
Format – Fireside chat and one-on-one investor meetings
Date and Time – Wednesday, Nov. 15, 2023 at 12:40pm ET / 9:40am PT
Piper Sandler 35th Annual Healthcare Conference, New York, NY
Format – Fireside chat and one-on-one investor meetings
Date and Time – Wednesday, Nov. 29, 2023 at 2:00pm ET / 11:00am PT
Evercore ISI 6th Annual HealthCONx Conference, Miami, FL
Format – Fireside chat and one-on-one investor meetings
Date and Time – Thursday, Nov. 30, 2023 at 10:25am ET / 7:25am PT
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. It is developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonistPD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and a planned Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. Its preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody for the treatment of autoimmune and inflammatory diseases. In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist antibody (Jemperli (dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn and X.
Contact:
Nick Montemarano
Senior Director, Investor Relations and Strategic Communications
858.732.0178
investors@anaptysbio.com


The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.